Cantor Fitzgerald has a “Overweight” rating and a $7.00 price objective on the stock. The consensus estimate for Mereo BioPharma Group’s current full-year earnings is ($0.03) per share.

Cantor Fitzgerald currently has a “Overweight” rating and a $46.00 price objective on the stock. The consensus estimate for Sanara MedTech’s current full-year earnings is ($1.10) per share.

On Friday, Cantor Fitzgerald reiterated its Overweight rating on Compass Pathways plc (NASDAQ:CMPS), a life sciences company focused on developing psilocybin therapy for mental health conditions.

EXCLUSIVE: Strange Darling‘s Willa Fitzgerald is starring opposite Russell Crowe and Harry Lawtey in Walden Media’s Cold War thriller Billion Dollar Spy, we can tell you first. Fitzgerald will ...

EXCLUSIVE: Strange Darling‘s Willa Fitzgerald is starring opposite Russell Crowe and Harry Lawtey in Walden Media’s Cold War thriller Billion Dollar Spy, we can tell you first. Fitzgerald will play ...

The City of St. Joseph is honoring the local artist responsible for two buildings that soon will be celebrating 100 ...

Around 50 community members gathered at the Santa Cruz Museum of Art and History on a brisk and sunny Saturday morning to ...

Clustered around the city's port on the banks of the St. Lawrence River are the quaint stone buildings and narrow, winding streets of Old Québec. This historic neighborhood (and UNESCO World ...

On Thursday, Cantor Fitzgerald reaffirmed its Overweight rating on shares of Summit Therapeutics plc (NASDAQ:SMMT), a biopharmaceutical company. According to InvestingPro data, the stock currently ...

Search for a state or federal candidate to see the donors and industries that support them. Ballot measures allow voters to vote directly on a law or policy change. Explore the ballot measures ...